Appendix A. Search strategies

Appendix B. Concurrence with Institute of Medicine standards for systematic reviews and for guidelines

Table S1. Summary table: diagnostic testing for liver fibrosis (by biopsy)

Table S2. Evidence profile: diagnostic testing for liver fibrosis (by biopsy)

Table S3. Summary table: HCV infection as independent predictor of CKD progression

Table S4. Evidence profile: HCV infection as independent predictor of CKD progression

Table S5. Summary table: treatment with direct-acting antiviral regimens in chronic HCV-infected CKD patients

Table S6. Evidence profile: treatment with direct-acting antiviral regimens in chronic HCV-infected CKD patients

Table S7. Summary table: treatment with direct-acting antiviral regimens in kidney transplant recipients with chronic HCV infection

Table S8. Evidence profile: treatment with direct-acting antiviral regimens in kidney transplant recipients with chronic HCV infection

Table S9. Summary table: isolation of HCV patients receiving hemodialysis

Table S10. Evidence profile: isolation of HCV patients receiving hemodialysis

Table S11. Summary table: transplantation versus waitlist among patients with HCV infection

Table S12. Evidence profile: transplantation versus waitlist among patients with HCV infection

Table S13. Summary table: HCV infection as predictor of death among kidney transplant recipients

Table S14. Evidence profile: HCV infection as predictor of death and graft loss among kidney transplant recipients

Table S15. Summary table: clinical outcomes of HCV-positive kidney transplant recipients from HCV-positive donors

Table S16. Summary table: induction and immunosuppression in kidney transplant recipients with HCV infection

Table S17. Summary table: HCV treatment of HCV-associated glomerular disease

Table S18. Evidence profile: HCV treatment of HCV-associated glomerular disease